Braskem stock trades at low levels as earnings highlight weak margins

Braskem S.A. (ISIN US10554K1025) stock continues to struggle, with its New York-listed ADR trading close to multi-year lows as of August 31, 2026, even after reporting a profitable quarter on the headline EPS level but still posting negative margins and return on equity.

ADR price lags well behind key averages

According to recent market data for the Braskem ADR on the New York Stock Exchange, Braskem shares opened at $1.66 on August 31, 2026, which represented a 1.5% decline at the open and placed the stock far below its short- and long-term trend indicators. One same-day consensus snapshot noted that the opening level of $1.66 sat well under the 50-day moving average of $2.31 and the 200-day moving average of $3.40, highlighting how far the ADR has retreated from its recent trading ranges.

Technical commentary on the ADR shows the instrument quoted at $1.68 intraday on August 31, 2026, in U.S. dollars, underscoring that the price has been fluctuating just above the mid-$1 range rather than returning toward the moving-average band. A technical analysis overview lists $1.68 USD as the live quote snapshot at 10:34 a.m. UTC-4 on August 31, 2026, which aligns closely with the $1.66 opening level cited in separate market coverage and reinforces the impression of a depressed trading range.

Latest quarter shows profit but deep structural weakness

The most recent reported quarter for Braskem, released on June 26, 2026, offers a mixed picture in which strong revenue and earnings per share coexist with negative profitability ratios. The same consensus-focused article notes that Braskem reported revenue of $4.20 billion for that quarter, which is a sizable top line for a chemical producer and indicates solid sales volumes across its resin and petrochemical product portfolio.

On the bottom line, Braskem delivered quarterly earnings per share of $1.61 in this latest report for the quarter ended June 26, 2026, giving investors a positive EPS number but not resolving concerns around the underlying quality of profits. The coverage indicates that the company recorded a net margin of negative 7.28% in the period, meaning that for every $100 of revenue, Braskem lost $7.28 after all expenses, financial items, and taxes. That loss ratio is particularly striking because it coexists with positive EPS, hinting at the presence of non-recurring items, accounting effects, or regional performance differences that investors must analyze more deeply.

Return on equity metrics deepen the picture of structural weakness. Braskem’s most recent quarter came with a reported return on equity of negative 67.75%, according to the consensus snapshot, which signals that the company destroyed shareholder value during the period instead of generating attractive returns on its equity base. When a company reports negative return on equity of 67.75% alongside negative net margins, it suggests that debt, asset impairments, or fair value adjustments have a heavy impact, and that management needs to address balance-sheet and operational challenges rather than relying on headline EPS alone.

Analysts captured in the same coverage expect Braskem to post full-year EPS of 1.58 for the current fiscal year 2026. That forecast implies a modest reduction compared with the latest quarterly run rate of $1.61 EPS, indicating that the market anticipates volatility across the remaining quarters, potentially from swings in resin pricing, feedstock costs, or currency effects in the company’s core Brazilian and broader Latin American operations.

Valuation and consensus context for investors

The combination of a $1.66 opening price on August 31, 2026, and a 50-day moving average of $2.31 suggests that Braskem’s ADR is trading roughly 28% below its shorter-term trend level. When compared with the 200-day moving average of $3.40, the gap expands further, with the current price less than half that longer-term reference level. For investors, these quantitative gaps highlight a depressed valuation relative to where the market had been willing to trade the shares over recent months.

This depressed price region sits against a backdrop of earnings that, while positive on a per-share basis, reflect deeply negative margins and return metrics. As long as Braskem’s net margin remains at negative 7.28% and return on equity stays around negative 67.75%, many portfolio managers are likely to view the stock as high risk despite the low absolute share price. The consensus expectation of full-year EPS of 1.58 in 2026 indicates that the market still expects Braskem to generate earnings, but it does not yet imply a clear path back to healthy profitability ratios.

From a risk perspective, the large negative return on equity underscores that Braskem’s capital structure and asset base may be under pressure. Chemical producers such as Braskem typically face cyclical swings in demand for plastics and industrial inputs, and the latest quarter’s negative net margin suggests that the company is in a weaker part of that cycle or dealing with company-specific cost or pricing challenges. For investors, the key question is whether future quarters can move net margin back into positive territory without relying solely on one-off items or favorable currency moves.

Resin and petrochemical portfolio underpin revenue scale

Braskem’s ability to report revenue of $4.20 billion in the quarter ended June 26, 2026, reflects the scale of its operations across basic petrochemicals, polyethylene, polypropylene, and other resin products that feed into packaging, automotive, and consumer-goods applications. Although the latest financial snapshot does not break down the revenue by segment, the sheer size of the top line indicates that the company continues to sell large volumes globally despite pressure on margins.

Historically, Braskem has positioned itself as a major supplier of thermoplastic resins, with a significant footprint in the Americas and selected international markets. Revenue performance in the latest quarter suggests that this commercial footprint remains intact, even as profitability metrics signal that the company is not currently capturing enough margin on those sales. For investors, this combination of strong top-line scale and weak bottom-line profitability points toward operational and cost-management levers rather than purely demand-related issues.

Management’s strategy in upcoming quarters will likely focus on improving margins by optimizing feedstock sourcing, enhancing plant utilization, and reviewing pricing in key markets. Given the negative net margin of 7.28% and negative return on equity of 67.75%, incremental efficiency gains alone may not be sufficient; more substantial restructuring, asset optimization, or portfolio adjustments could be required to restore sustainable profitability. The consensus forecast for full-year EPS of 1.58 in 2026 indicates that analysts expect some improvement relative to prior periods, but not a full turnaround yet.

Representative product: thermoplastic resins for packaging and industry

A representative product category that helps explain Braskem’s revenue scale is its range of thermoplastic resins used in flexible and rigid packaging, automotive components, and industrial applications. These resins, including various grades of polyethylene and polypropylene, are sold to converters and manufacturers that turn them into films, bottles, containers, and molded parts across consumer and industrial supply chains. When Braskem reports quarterly revenue of $4.20 billion, much of that comes from ongoing demand for such everyday materials, even if pricing and cost pressures compress margins.

Stock remains depressed as of latest trading session

As of August 31, 2026, based on intraday technical data, the Braskem ADR trades around $1.68 USD on the New York Stock Exchange, reinforcing that the share price has not yet recovered toward its 50-day and 200-day moving averages and remains in a low single-dollar range. For U.S. retail investors, this depressed level combined with negative net margin and negative return on equity underscores that Braskem stock currently offers exposure to a cyclical chemical producer with significant operational challenges, rather than a stable income-generating industrial name.

Fact box

Company: Braskem S.A.

ISIN: US10554K1025

Ticker: BAK

Exchange: New York Stock Exchange (ADR)

Price (as of August 31, 2026, 10:34 a.m. ET): $1.68 USD

Market cap: not specified in available sources

Sector / Industry: Chemicals / Petrochemicals and Resins

Index membership: not part of a major U.S. large-cap index as of the latest data